Literature DB >> 10939226

Stimulant treatment for children: a community perspective.

A Angold1, A Erkanli, H L Egger, E J Costello.   

Abstract

OBJECTIVE: To examine the use of prescribed stimulants in relation to research diagnoses of attention-deficit hyperactivity disorder (ADHD) in a community sample of children.
METHOD: Data from 4 annual waves of interviews with 9- to 16-year-olds from the Great Smoky Mountains Study were analyzed.
RESULTS: Over a 4-year period, almost three quarters of children with an unequivocal diagnosis of ADHD received stimulant medications. However, girls and older children with ADHD were less likely to receive such treatment. Most children with impairing ADHD symptoms not meeting full criteria for DSM-III-R ADHD did not receive stimulant treatment. Stimulant treatment in this group was significantly related to the level of symptoms reported by parents and teachers and was much more common in individuals who met criteria for oppositional defiant disorder. The majority of individuals who received stimulants were never reported by their parents to have any impairing ADHD symptoms. They did have higher levels of nonimpairing parent-reported ADHD symptoms, higher levels of teacher-reported ADHD symptoms, and interviewer-observed ADHD behaviors, but these typically fell far below the threshold for a DSM-III-R diagnosis of ADHD.
CONCLUSIONS: In this area of the Great Smoky Mountains, stimulant treatment was being used in ways substantially inconsistent with current diagnostic guidelines.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10939226     DOI: 10.1097/00004583-200008000-00009

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  46 in total

Review 1.  Methylphenidate in the treatment of children with attention-deficit hyperactivity disorder.

Authors:  B Vitiello
Journal:  CMAJ       Date:  2001-11-27       Impact factor: 8.262

2.  Racial/ethnic differences in the use of psychotropic medication in high-risk children and adolescents.

Authors:  Laurel K Leslie; Jill Weckerly; John Landsverk; Richard L Hough; Michael S Hurlburt; Patricia A Wood
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2003-12       Impact factor: 8.829

3.  Foreword -- ADHD in the scientific and political context.

Authors:  Jan K Buitelaar; Aribert Rothenberger
Journal:  Eur Child Adolesc Psychiatry       Date:  2004       Impact factor: 4.785

4.  Pediatric psychopharmacology: Too much and too little.

Authors:  Eric Taylor
Journal:  World Psychiatry       Date:  2013-06       Impact factor: 49.548

5.  Geographic variation and disparity in stimulant treatment of adults and children in the United States in 2008.

Authors:  Douglas C McDonald; Sarah Kuck Jalbert
Journal:  Psychiatr Serv       Date:  2013-11-01       Impact factor: 3.084

6.  The use of stimulant medication in the treatment of attention deficit hyperactivity disorder.

Authors: 
Journal:  Paediatr Child Health       Date:  2002-12       Impact factor: 2.253

Review 7.  Quantitative electroencephalography and attention-deficit/hyperactivity disorder: implications for clinical practice.

Authors:  Vincent J Monastra
Journal:  Curr Psychiatry Rep       Date:  2008-10       Impact factor: 5.285

Review 8.  Treatment of preschoolers with attention-deficit/hyperactivity disorder.

Authors:  Desiree W Murray
Journal:  Curr Psychiatry Rep       Date:  2010-10       Impact factor: 5.285

9.  The Prevalence of ADHD in a Population-Based Sample.

Authors:  Andrew S Rowland; Betty J Skipper; David M Umbach; David L Rabiner; Richard A Campbell; Albert J Naftel; Dale P Sandler
Journal:  J Atten Disord       Date:  2013-12-11       Impact factor: 3.256

10.  Preschool ADHD Diagnosis and Stimulant Use Before and After the 2011 AAP Practice Guideline.

Authors:  Alexander G Fiks; Michelle E Ross; Stephanie L Mayne; Lihai Song; Weiwei Liu; Jennifer Steffes; Banita McCarn; Robert W Grundmeier; A Russell Localio; Richard Wasserman
Journal:  Pediatrics       Date:  2016-11-15       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.